939986-54-6

Usage

Uses

Used in Pharmaceutical Research and Development:
Used in Medicinal Chemistry:
In the field of medicinal chemistry, [1-(2-Chloro-thiazol-5-ylMethyl)-piperidin-4-yl]-carbaMic acid tert-butyl ester, 98+% C14H22ClN3O2S, MW: 331.86 is used as a starting material or intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for further modification and functionalization, enabling the development of new drugs with improved efficacy and selectivity.
Used in Drug Design and Optimization:
[1-(2-Chloro-thiazol-5-ylMethyl)-piperidin-4-yl]-carbaMic acid tert-butyl ester, 98+% C14H22ClN3O2S, MW: 331.86 is also used in drug design and optimization processes. Its structural features can be exploited to design new drugs with specific target interactions, potentially leading to the development of more effective treatments for various diseases and conditions.
Used in Laboratory Settings:
Due to its high purity (98+%), [1-(2-Chloro-thiazol-5-ylMethyl)-piperidin-4-yl]-carbaMic acid tert-butyl ester, 98+% C14H22ClN3O2S, MW: 331.86 is suitable for use in laboratory settings. It can be employed in various experiments and assays to study its biological activities, interactions with target proteins, and potential side effects, contributing to the advancement of pharmaceutical research.

Upstream product

• 105827-91-6 α-Cl-β-thiazolyl chloride 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Design and synthesis of piperidine derivatives as novel human heat shock protein 70 inhibitors for the treatment of drug-resistant tumors

Abstract HSP70 is a potential target for tumour treatment. HSP70 plays significant roles in several biological processes, including the regulation of apoptosis. In this study, piperidine derivatives were designed as novel HSP70 inhibitors based on virtual fragment screening performed in Dock 4.0, Discovery Studio 2.5 and SYBYL 6.9. A total of 67 novel piperidine derivatives were synthesized. Cell viability assays were performed in 16 cancer cell lines. The emphasis was placed on lapatinib-resistant breast cancer cells (BT/LapR1.0, MDA-MB-361, SK/LapR1.0, and MDA-MB-453). The compounds HSP70-36/37/40/43/46 significantly inhibited the proliferation of human breast cancer cells. Compound HSP70-36 inhibited the growth of BT474 and BT/LapR1.0 cells with IC50 values of 1.41 μM and 1.47 μM, respectively. The binding affinity of HSP70-36/HSP70 was evaluated by surface plasmon resonance and yielded Kd values of 2.46 μM. The LD50 was 869.0 mgkg-1. These data suggest that HSP70-36 may be a potential candidate compound for tumour treatment.